La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Sarepta Therapeutics Gestione
Gestione criteri di controllo 4/4
Sarepta Therapeutics' Il CEO è Doug Ingram, nominato in Jun2017, e ha un mandato di 7.17 anni. la retribuzione annua totale è $ 1.66M, composta da 48.1% di stipendio e 51.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.41% delle azioni della società, per un valore di $ 53.58M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.7 anni e 8.2 anni.
Informazioni chiave
Doug Ingram
Amministratore delegato
US$1.7m
Compenso totale
| Percentuale dello stipendio del CEO | 48.1% |
| Mandato del CEO | 7.3yrs |
| Proprietà del CEO | 0.4% |
| Durata media del management | 3.8yrs |
| Durata media del Consiglio di amministrazione | 8.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
The Play On Sarepta Therapeutics
Sep 26Sarepta Therapeutics Muscles Up In DMD Race
Sep 19Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05
Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$47m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$2m | US$800k | -US$536m |
| Sep 30 2023 | n/a | n/a | -US$691m |
| Jun 30 2023 | n/a | n/a | -US$908m |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$125m | US$740k | -US$703m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$507m |
| Mar 31 2022 | n/a | n/a | -US$357m |
| Dec 31 2021 | US$2m | US$730k | -US$419m |
| Sep 30 2021 | n/a | n/a | -US$486m |
| Jun 30 2021 | n/a | n/a | -US$634m |
| Mar 31 2021 | n/a | n/a | -US$704m |
| Dec 31 2020 | US$1m | US$669k | -US$554m |
| Sep 30 2020 | n/a | n/a | -US$601m |
| Jun 30 2020 | n/a | n/a | -US$530m |
| Mar 31 2020 | n/a | n/a | -US$656m |
| Dec 31 2019 | US$1m | US$650k | -US$715m |
| Sep 30 2019 | n/a | n/a | -US$620m |
| Jun 30 2019 | n/a | n/a | -US$570m |
| Mar 31 2019 | n/a | n/a | -US$403m |
| Dec 31 2018 | US$1m | US$650k | -US$362m |
| Sep 30 2018 | n/a | n/a | -US$245m |
| Jun 30 2018 | n/a | n/a | -US$216m |
| Mar 31 2018 | n/a | n/a | -US$170m |
| Dec 31 2017 | US$57m | US$338k | -US$51m |
Compensazione vs Mercato: La retribuzione totale di Doug ($USD 1.66M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 13.17M ).
Compensazione vs guadagni: La retribuzione di Doug è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Doug Ingram (61 yo)
7.3yrs
Mandato
US$1,661,338
Compensazione
Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as an Independent Director of Rela...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 7.3yrs | US$1.66m | 0.41% $ 48.6m | |
| Executive VP & CFO | 3.8yrs | US$3.71m | 0.036% $ 4.2m | |
| Executive VP & Chief Technical Operations Officer | 1.8yrs | US$3.52m | 0.018% $ 2.2m | |
| Executive VP | 3.8yrs | US$3.72m | 0.076% $ 9.0m | |
| Executive VP | 3.8yrs | US$3.58m | 0.018% $ 2.1m | |
| Executive Director of Investor Relations and Corporate Communications | no data | Nessun dato | Nessun dato | |
| Executive VP & Chief People Officer | 2.9yrs | Nessun dato | Nessun dato | |
| Executive VP and Chief of Global Policy & Advocacy Officer | 5yrs | Nessun dato | Nessun dato | |
| Executive VP & Chief Customer Officer | 3.8yrs | Nessun dato | 0.023% $ 2.7m | |
| Senior VP | 1.7yrs | Nessun dato | Nessun dato | |
| Controller & VP | 7.5yrs | US$911.89k | Nessun dato | |
| Senior Manager of Investor Relations | no data | Nessun dato | Nessun dato |
3.8yrs
Durata media
50yo
Età media
Gestione esperta: Il team dirigenziale di SRPT è considerato esperto (durata media dell'incarico 3.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 7.3yrs | US$1.66m | 0.41% $ 48.6m | |
| Independent Chairwoman | 15.5yrs | US$594.99k | 0.21% $ 24.8m | |
| Chairman of Corporate Strategy Board & Independent Non-Employee Director | 14.3yrs | US$546.99k | 0.022% $ 2.6m | |
| Independent Director | 9.3yrs | US$563.65k | 3.33% $ 396.0m | |
| Member of Strategic & Scientific Advisory Board | 9.1yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.8yrs | Nessun dato | Nessun dato | |
| Member of Strategic & Scientific Advisory Board | 9.1yrs | Nessun dato | Nessun dato | |
| Independent Non-Employee Director | 9.3yrs | US$553.34k | 0.017% $ 2.0m | |
| Member of Strategic & Scientific Advisory Board | 7.5yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.8yrs | Nessun dato | Nessun dato | |
| Member of Strategic & Scientific Advisory Board | 7.5yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.8yrs | Nessun dato | Nessun dato |
8.3yrs
Durata media
71yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SRPT sono considerati esperti (durata media dell'incarico 8.2 anni).